Charles Schwab Investment Management Inc Fate Therapeutics Inc Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 733,911 shares of FATE stock, worth $946,745. This represents 0.0% of its overall portfolio holdings.
Number of Shares
733,911
              Previous 703,825
              
        
           4.27%
        
      
          
        Holding current value
$946,745
            Previous $556,000
            
        
           47.66%
        
      
          
        % of portfolio
0.0%
            Previous 0.0%
          
        Shares
	  32 transactions
	
  Others Institutions Holding FATE
# of Institutions
152Shares Held
83.4MCall Options Held
179KPut Options Held
13.4K- 
    
      Redmile Group, LLC San Francisco, CA12.9MShares$16.6 Million1.75% of portfolio
- 
    
      Black Rock Inc. New York, NY10.1MShares$13 Million0.0% of portfolio
- 
    
      Vanguard Group Inc Valley Forge, PA8.77MShares$11.3 Million0.0% of portfolio
- 
    
      Ken Griffin Citadel Advisors LLC | Chicago, Il4.54MShares$5.86 Million0.0% of portfolio
- 
    
      Jpmorgan Chase & CO New York, NY3.4MShares$4.38 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $125M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...